The Conversation (0)
SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases, today announced that members of its management team will participate in the following investor conferences in February:
Guggenheim Securities Emerging Outlook: Biotech Summit
Date:Â February 11, 2026
Time: 10:30 a.m. ET
Format:Â Fireside Chat
Location: New York, NY
Oppenheimer 36th Annual Healthcare Life Sciences Conference
Date:Â February 25, 2026
Time: 8:40 a.m. ET
Format:Â Fireside Chat
Location: Virtual
To access a live webcast of these events, as well as an archived recording, please visit the Investors & Media section of the Company's website at www.sab.bio. Â
About SAB BIO
SAB BIO is a clinical-stage biopharmaceutical company focused on developing multi-specific, high-potency, human immunoglobulin G (hIgG) to treat and prevent immune and autoimmune disorders. The Company's lead candidate, SAB-142, targets autoimmune T1D with a disease-modifying therapeutic approach that aims to change the T1D treatment paradigm by delaying onset and potentially preventing disease progression of Stage 3 T1D patients. Using advanced genetic engineering and antibody science, SAB BIO developed a proprietary technology which holds the potential to generate additional novel therapeutic candidates utilizing the human immune response, without the need for human donors or convalescent plasma. SAB BIO has optimized genetic engineering in the development of transchromosomic cattle, or Tc-Bovineâ„¢, to produce hIgG. SAB BIO's drug development production system is able to generate a diverse repertoire of specifically targeted, high-potency, hIgGs that can address a wide range of serious unmet needs in human diseases. For more information, visit www.sab.bio.
CONTACTS
Investors:
Cristi Barnett
ir@sab.bio
Media:
Sheila Carlson
media@sab.bio
